.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Healthtrust
Colorcon
US Army
US Department of Justice
Baxter
Citi
Cantor Fitzgerald
Chinese Patent Office
Boehringer Ingelheim

Generated: December 18, 2017

DrugPatentWatch Database Preview

DOXEPIN HYDROCHLORIDE Drug Profile

« Back to Dashboard

When do Doxepin Hydrochloride patents expire, and when can generic versions of Doxepin Hydrochloride launch?

Doxepin Hydrochloride is a drug marketed by Amneal Pharms Co, Dava Pharms Inc, Mylan Pharms Inc, New River, Par Pharm, Purepac Pharm, Quantum Pharmics, Sandoz, Sun Pharm Industries, Watson Labs, Watson Labs Teva, Pharm Assoc, Silarx, Teva Pharms, Wockhardt, and Actavis Elizabeth. and is included in fifty-six NDAs.

The generic ingredient in DOXEPIN HYDROCHLORIDE is doxepin hydrochloride. There are seven drug master file entries for this compound. Thirty suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the doxepin hydrochloride profile page.
Drug patent expirations by year for DOXEPIN HYDROCHLORIDE

Pharmacology for DOXEPIN HYDROCHLORIDE

Medical Subject Heading (MeSH) Categories for DOXEPIN HYDROCHLORIDE

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
SandozDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL071487-001Mar 2, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Purepac PharmDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL072386-001Sep 8, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Sun Pharm IndustriesDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL071521-001Feb 18, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson LabsDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL070955-001May 15, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
SandozDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL071562-001Mar 2, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson LabsDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL070952-001Mar 4, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson LabsDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL072986-001Mar 29, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson LabsDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL071239-001Apr 30, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Par PharmDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL071669-001Nov 9, 1987RXNoYes► Subscribe► Subscribe► Subscribe
Purepac PharmDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL072110-001Sep 8, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: DOXEPIN HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
New RiverDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL016987-004Approved Prior to Jan 1, 1982► Subscribe► Subscribe
New RiverDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL016987-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
New RiverDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL016987-006Approved Prior to Jan 1, 1982► Subscribe► Subscribe
New RiverDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL016987-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
New RiverDOXEPIN HYDROCHLORIDEdoxepin hydrochlorideCAPSULE;ORAL016987-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Daiichi Sankyo
Chinese Patent Office
US Army
Boehringer Ingelheim
Argus Health
Dow
Express Scripts
Harvard Business School
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot